CG Oncology, Inc. led the latest group of private biotechnology companies that completed $100m-plus venture capital mega-rounds, with a $120m series E financing announced on 15 November, followed closely behind by MBX Biosciences, Inc.’s $115m series B round revealed a day earlier.
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
TauRx Grosses $119m From Warrant Exercise
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.

More from Financing
More from Business
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.